

Supplemental Table S2. Change from Baseline in eGFR and Albuminuria at Week 24—Full Analysis Set

Variable	Gemigliptin 50 mg (n=158)	Placebo (n=154)
eGFR, mL/min/1.73 m²		
Baseline		
Mean±SD	92.69±16.85	92.51±19.32
Week 24		
Mean±SD	93.82±17.85	94.51±18.68
Change from baseline at week 24		
LSM (SE)	1.46 (0.88)	1.95 (0.90)
95% CI for LSM	-0.27 to 3.20	0.17 to 3.73
LSM difference (SE)	-0.49 (1.26)	
95% CI for LSM difference	-2.97 to 1.99	
<i>P</i> value ^a	0.6989	
Week 52		
Mean±SD	93.62±18.36	94.72±19.00
Change from baseline at week 52		
LSM (SE) ^b	0.88 (0.81)	2.07 (0.84)
95% CI for LSM	-0.72 to 2.48	0.41 to 3.72
Albuminuria, mg/g		
Baseline		
Mean±SD	45.65±122.44	41.84±77.70
Week 24		
Mean±SD	36.60±89.35	69.19±296.03
Change from baseline at week 24		
LSM (SE)	-8.83 (16.92)	29.55 (17.66)
95% CI for LSM	-42.15 to 24.49	-5.22 to 64.32
LSM difference (SE)	-38.38 (24.47)	
95% CI for LSM difference	-86.55 to 9.79	
<i>P</i> value ^a	0.1179	
Week 52		
Mean±SD	37.61±91.37	65.18±283.34
Change from baseline at week 52		
LSM (SE) ^b	-6.44 (15.61)	21.56 (16.15)
95% CI for LSM	-37.16 to 24.29	-10.24 to 53.35

eGFR, estimated glomerular filtration rate; SD, standard deviation; LSM, least square mean; SE, standard error; CI, confidence interval.

^aTesting for change within-treatment group (paired *t* test [*t*] or Wilcoxon signed rank test [*w*]); ^bMixed model including treatment, baseline hemoglobin A1c, baseline eGFR, visit, treatment-by-visit interaction as fixed effects, subject as random effect.